Sermorelin is one of the few peptides that moved from mainstream endocrinology into the modern optimization space, and in this episode Ashishpal Singh, PA‑C and founder of Mool Med, explains why that matters by unpacking its FDA history, mechanisms as a GHRH analogue (not GH), and the commercial reasons it left retail pharmacies. He dives into how sermorelin can support pulsatile, sleep‑linked growth hormone, and where it fits clinically: TRT/HRT patients with blunted recovery, GLP‑1 users who want to lose fat while preserving muscle, perimenopausal women with early sarcopenia, and athletes rehabbing injuries. Listeners come away with a clear, no‑hype framework for when sermorelin is useful, when it isn’t, and how to use it intelligently alongside sleep, light, training, and foundational hormones
Chapters
00:00 Introduction to sermorelin and its history
00:28 Why understanding peptides like sermorelin matters
01:25 The research background and FDA approval of sermorelin
02:19 How sermorelin stimulates the pituitary to release growth hormone
03:13 Differences between sermorelin and direct growth hormone therapy
05:36 The FDA story and clinical use in pediatrics
07:01 Comparison of sermorelin with other growth hormone secretagogues
08:55 Who benefits from sermorelin: candidates and applications
11:03 Sermorelin for muscle maintenance, aging, and injury recovery
12:49 Using sermorelin with GLP-1 therapies and metabolic health
16:10 Special considerations for perimenopausal women and sarcopenia
17:07 Dosing, safety, and sourcing of sermorelin
18:58 Integrating sermorelin into a holistic health protocol
21:45 Final thoughts: safety, sourcing, and responsible use
